Clinical Trial Update: Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing different concentrations of SPARC1102 for allergic conjunctivitis has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• SPARC1102

Snippet

Sponsor: Sun Pharma Advanced Research Company Limited | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2016-05-20